{
    "hands_on_practices": [
        {
            "introduction": "Understanding the clinical variability of Fragile X syndrome in heterozygous females requires a quantitative grasp of X-inactivation. This exercise guides you to build a foundational mathematical model from first principles. By formalizing the relationship between the proportion of cells with an active mutant allele and the overall protein production, you will develop a clear, quantitative intuition for how X-inactivation skewing directly impacts the molecular phenotype in a carrier female .",
            "id": "5145628",
            "problem": "A heterozygous female carries one normal Fragile X Mental Retardation 1 (FMR1) allele on one X chromosome and one mutant FMR1 allele on the other X chromosome. Fragile X Messenger Ribonucleoprotein (FMRP) is produced by translation of FMR1 messenger ribonucleic acid (mRNA), following the Central Dogma of molecular biology (deoxyribonucleic acid $\\rightarrow$ ribonucleic acid $\\rightarrow$ protein). In somatic cells, X-inactivation (lyonization) results in only one active X chromosome per cell. Let $p$ denote the fraction of cells in which the mutant X chromosome is inactivated, so that the normal X chromosome is active in those cells, and let $1 - p$ denote the fraction of cells in which the mutant X chromosome is active. Assume:\n- When the normal X chromosome is the active X, the cell produces a baseline FMRP amount that we normalize to $1$ (dimensionless).\n- When the mutant X chromosome is the active X, promoter hypermethylation and translational inefficiency reduce FMRP production to a fraction $\\alpha$ of the baseline, with $0 \\leq \\alpha \\leq 1$. For a full mutation with near-complete silencing, $\\alpha \\approx 0$.\n\nTreat cells as identically and independently patterned with respect to X-inactivation, and assume FMRP production scales linearly with the activity state of the expressed allele. Under these assumptions, derive the expected cellular FMRP production across the mosaic cell population as a single closed-form expression in terms of $p$ and $\\alpha$. Express the final answer as a dimensionless ratio relative to the wild-type female baseline. No rounding is required.",
            "solution": "The user wants me to solve the problem by following these steps:\n1.  **Extract Givens:**\n    *   The subject is a heterozygous female with one normal and one mutant Fragile X Mental Retardation 1 (FMR1) allele.\n    *   FMR1 messenger ribonucleic acid (mRNA) is translated to produce Fragile X Messenger Ribonucleoprotein (FMRP).\n    *   Somatic cells undergo X-inactivation, leaving one active X chromosome per cell.\n    *   $p$ is the fraction of cells where the mutant X chromosome is inactivated (i.e., the normal X is active).\n    *   $1-p$ is the fraction of cells where the mutant X chromosome is active.\n    *   FMRP production from a cell with an active normal X chromosome is normalized to $1$.\n    *   FMRP production from a cell with an active mutant X chromosome is $\\alpha$, where $0 \\leq \\alpha \\leq 1$.\n    *   The model assumes cells are identically and independently patterned, and FMRP production scales linearly with allele activity.\n    *   The task is to derive the expected cellular FMRP production for the heterozygous female as a closed-form expression in terms of $p$ and $\\alpha$.\n    *   The final answer must be a dimensionless ratio relative to the wild-type female baseline.\n\n2.  **Validate Using Extracted Givens:**\n    *   **Scientific or Factual Soundness:** The problem is scientifically grounded. It accurately describes the basic molecular genetics of an X-linked disorder, including the FMR1 gene, FMRP protein, X-inactivation (lyonization), and the concept of cellular mosaicism in a heterozygous female. The model, while a simplification, is a standard and valid approach for quantitative biological modeling.\n    *   **Well-Posed:** The problem is well-posed. It provides all necessary variables ($p$, $\\alpha$) and a clear set of assumptions to derive a unique and meaningful solution. The objective is explicitly stated.\n    *   **Objective:** The language is formal, precise, and objective, using standard terminology from genetics and mathematics.\n    *   **Completeness and Consistency:** The problem is self-contained and internally consistent. The fractions of the two cell populations, $p$ and $1-p$, sum to $1$, covering all possibilities. The assumptions are clearly stated and do not contradict one another.\n    *   **Realism and Feasibility:** The assumptions (linear scaling, discrete production levels) are reasonable simplifications for creating a tractable model of a complex biological system. The parameter ranges are physically and biologically plausible.\n    *   **Other Flaws:** The problem does not exhibit any other flaws such as being ill-posed, pseudo-profound, or unverifiable. It is a legitimate problem in quantitative biology.\n\n3.  **Verdict and Action:**\n    *   The problem is **valid**. The solution process will proceed.\n\nThe system described is a mosaic cell population composed of two distinct subpopulations, distinguished by which X chromosome is active. We are asked to find the expected FMRP production across this entire population. The expected value is calculated as the weighted average of the FMRP production from each subpopulation, where the weights are the respective fractions of each subpopulation.\n\nLet the two subpopulations be denoted as Population $1$ and Population $2$.\n\nFor Population $1$:\n-   The active chromosome is the normal X chromosome.\n-   The fraction of cells in this population is given as $p$.\n-   The FMRP production level per cell is normalized to $P_1 = 1$.\n\nFor Population $2$:\n-   The active chromosome is the mutant X chromosome.\n-   The fraction of cells in this population is given as $1-p$.\n-   The FMRP production level per cell is $P_2 = \\alpha$.\n\nThe expected cellular FMRP production for the heterozygous female, which we can denote as $\\langle FMRP \\rangle_{het}$, is the sum of the production from each population multiplied by its fractional representation:\n$$\n\\langle FMRP \\rangle_{het} = (p \\times P_1) + ((1-p) \\times P_2)\n$$\nSubstituting the given production levels:\n$$\n\\langle FMRP \\rangle_{het} = (p \\times 1) + ((1-p) \\times \\alpha)\n$$\n$$\n\\langle FMRP \\rangle_{het} = p + \\alpha(1-p)\n$$\nThis expression can be expanded and rearranged:\n$$\n\\langle FMRP \\rangle_{het} = p + \\alpha - \\alpha p = \\alpha + p(1-\\alpha)\n$$\nThe problem requires the final answer to be expressed as a dimensionless ratio relative to the wild-type female baseline. A wild-type female possesses two normal X chromosomes. In each of her somatic cells, one X chromosome is randomly inactivated, leaving one active, normal X chromosome. Therefore, every cell in a wild-type female produces the baseline amount of FMRP. The production level in this case, which we denote $\\langle FMRP \\rangle_{wt}$, is constant across all cells and is equal to the normalized value of $1$.\n$$\n\\langle FMRP \\rangle_{wt} = 1\n$$\nThe required dimensionless ratio $R$ is the expected production in the heterozygous female divided by the production in the wild-type female:\n$$\nR = \\frac{\\langle FMRP \\rangle_{het}}{\\langle FMRP \\rangle_{wt}} = \\frac{\\alpha + p(1-\\alpha)}{1}\n$$\nThus, the final expression for the ratio is:\n$$\nR = \\alpha + p(1-\\alpha)\n$$\nThis is the closed-form expression for the expected cellular FMRP production in the heterozygous female, relative to the wild-type female baseline, in terms of the given parameters $p$ and $\\alpha$.",
            "answer": "$$\\boxed{\\alpha + p(1-\\alpha)}$$"
        },
        {
            "introduction": "Building on the principles of cellular mosaicism, this next practice challenges you to integrate Mendelian inheritance with a probabilistic model of X-inactivation. You will calculate the expected proportion of affected offspring for a female carrier, explicitly accounting for the different outcomes in males and the variable expressivity in females. This problem hones the critical skills needed for genetic counseling, requiring you to synthesize multiple layers of biological and statistical information to arrive at a comprehensive risk assessment .",
            "id": "5145664",
            "problem": "A heterozygous female with a full mutation in the Fragile X Messenger Ribonucleoprotein 1 ($\\text{FMR1}$) gene has one $\\text{X}$ chromosome carrying a full mutation and one normal $\\text{X}$ chromosome. Consider a mating with an unaffected $\\text{XY}$ father, and assume a $1{:}1$ sex ratio and Mendelian segregation. For males who inherit the maternal full-mutation $\\text{X}$ chromosome, assume complete functional loss of Fragile X messenger ribonucleoprotein ($\\text{FMRP}$) and thus clinical affection. For females who inherit the full-mutation $\\text{X}$ chromosome, assume random $\\text{X}$-inactivation across $N = 100$ independent developmental domains relevant to neurocognitive phenotype, each domain independently inactivating the normal or mutant $\\text{X}$ with probability $1/2$. Let $K \\sim \\text{Binomial}(N, 1/2)$ be the number of domains in which the mutant $\\text{X}$ is active, and let the organism-level functional severity be $s_{f} = q = K/N$. Define an affected phenotype for females as $s_{f} \\geq \\tau$, with threshold $\\tau = 0.6$. Using only these assumptions and standard Mendelian inheritance, calculate the expected proportion of affected offspring (combining both sexes), explicitly accounting for sex, allele transmission, and the severity distribution induced by random $\\text{X}$-inactivation. Round your final expected proportion to four significant figures and express it as a decimal without a percentage sign.",
            "solution": "The problem statement has been evaluated and is deemed valid. It is scientifically grounded within the standard framework of Mendelian genetics and statistical modeling, well-posed with all necessary information provided, and objective in its formulation. We may therefore proceed with a formal solution.\n\nThe objective is to calculate the expected proportion of affected offspring from a specific mating. This is equivalent to finding the total probability of an offspring being affected, considering all possible outcomes.\n\nFirst, we establish the genetic framework based on Mendelian inheritance. The mother is heterozygous for the $\\text{FMR1}$ full mutation, with genotype denoted as $X^F X^n$, where $X^F$ carries the full mutation and $X^n$ is the normal allele. The father is an unaffected male, with genotype $X^n Y$.\n\nThe possible genotypes of the offspring and their respective probabilities, assuming Mendelian segregation and a $1{:}1$ sex ratio, are:\n1.  Female, heterozygous carrier ($X^F X^n$): Probability is $P(X^F X^n) = P(\\text{receives } X^F \\text{ from mother}) \\times P(\\text{receives } X^n \\text{ from father}) = \\frac{1}{2} \\times 1 \\times P(\\text{is female}) = \\frac{1}{2} \\times \\frac{1}{2} = \\frac{1}{4}$.\n2.  Female, homozygous normal ($X^n X^n$): Probability is $P(X^n X^n) = P(\\text{receives } X^n \\text{ from mother}) \\times P(\\text{receives } X^n \\text{ from father}) = \\frac{1}{2} \\times 1 \\times P(\\text{is female}) = \\frac{1}{2} \\times \\frac{1}{2} = \\frac{1}{4}$.\n3.  Male, with full mutation ($X^F Y$): Probability is $P(X^F Y) = P(\\text{receives } X^F \\text{ from mother}) \\times P(\\text{receives } Y \\text{ from father}) = \\frac{1}{2} \\times 1 \\times P(\\text{is male}) = \\frac{1}{2} \\times \\frac{1}{2} = \\frac{1}{4}$.\n4.  Male, normal ($X^n Y$): Probability is $P(X^n Y) = P(\\text{receives } X^n \\text{ from mother}) \\times P(\\text{receives } Y \\text{ from father}) = \\frac{1}{2} \\times 1 \\times P(\\text{is male}) = \\frac{1}{2} \\times \\frac{1}{2} = \\frac{1}{4}$.\n\nNext, we evaluate the phenotype (affected or unaffected) for each genotype.\n- Offspring with genotypes $X^n X^n$ and $X^n Y$ are unaffected as they do not carry the mutation.\n- According to the problem, males who inherit the full-mutation $\\text{X}$ chromosome ($X^F Y$) are clinically affected. The probability of an offspring being an affected male is therefore $P(\\text{Affected Male}) = P(X^F Y) = \\frac{1}{4}$.\n\nFor heterozygous females ($X^F X^n$), the phenotype depends on the process of random $\\text{X}$-inactivation. The severity, $s_f$, is defined as $s_f = K/N$, where $N=100$ is the number of independent developmental domains and $K$ is the number of domains where the mutant $\\text{X}$ chromosome is active. The variable $K$ follows a binomial distribution, $K \\sim \\text{Binomial}(N, p)$, with $N=100$ and $p=1/2$. A female is defined as affected if her severity $s_f$ meets or exceeds a threshold $\\tau = 0.6$.\n\nThe condition for a heterozygous female to be affected is $s_f \\geq \\tau$, which translates to:\n$$\n\\frac{K}{N} \\geq \\tau \\implies \\frac{K}{100} \\geq 0.6 \\implies K \\geq 60\n$$\nThus, the probability that a heterozygous female is affected, $P(\\text{Affected} | X^F X^n)$, is the probability of $K \\geq 60$. We calculate this probability:\n$$\nP(K \\geq 60) = \\sum_{k=60}^{100} \\binom{100}{k} \\left(\\frac{1}{2}\\right)^k \\left(1-\\frac{1}{2}\\right)^{100-k} = \\left(\\frac{1}{2}\\right)^{100} \\sum_{k=60}^{100} \\binom{100}{k}\n$$\nSince $N$ is large, we can use the normal approximation to the binomial distribution. The mean ($\\mu$) and standard deviation ($\\sigma$) of $K$ are:\n$$\n\\mu = Np = 100 \\times \\frac{1}{2} = 50\n$$\n$$\n\\sigma = \\sqrt{Np(1-p)} = \\sqrt{100 \\times \\frac{1}{2} \\times \\frac{1}{2}} = \\sqrt{25} = 5\n$$\nWe seek $P(K \\geq 60)$. Applying the continuity correction, we approximate this by finding the probability that a normally distributed random variable $X \\sim \\mathcal{N}(\\mu=50, \\sigma^2=25)$ is greater than or equal to $59.5$. We standardize this value by computing the Z-score:\n$$\nZ = \\frac{59.5 - \\mu}{\\sigma} = \\frac{59.5 - 50}{5} = \\frac{9.5}{5} = 1.9\n$$\nThe probability is then $P(Z \\geq 1.9)$, where $Z$ is a standard normal random variable. This is given by $1 - \\Phi(1.9)$, where $\\Phi$ is the cumulative distribution function of the standard normal distribution. Using a standard value for $\\Phi(1.9) \\approx 0.9712834$:\n$$\nP(K \\geq 60) \\approx 1 - \\Phi(1.9) \\approx 1 - 0.9712834 = 0.0287166\n$$\nThis is the probability that a heterozygous female is affected. The contribution of affected females to the total proportion of affected offspring is the probability of having a heterozygous female multiplied by her probability of being affected:\n$$\nP(\\text{Affected Female}) = P(X^F X^n) \\times P(\\text{Affected} | X^F X^n) \\approx \\frac{1}{4} \\times 0.0287166\n$$\nThe total expected proportion of affected offspring, $P(\\text{Affected})$, is the sum of the probabilities of being an affected male and an affected female:\n$$\nP(\\text{Affected}) = P(\\text{Affected Male}) + P(\\text{Affected Female}) = \\frac{1}{4} + \\frac{1}{4} P(K \\geq 60)\n$$\n$$\nP(\\text{Affected}) = \\frac{1}{4} (1 + P(K \\geq 60))\n$$\nSubstituting the calculated value:\n$$\nP(\\text{Affected}) \\approx \\frac{1}{4} (1 + 0.0287166) = \\frac{1.0287166}{4} = 0.25717915\n$$\nThe problem requires the final answer to be rounded to four significant figures.\n$$\n0.25717915 \\approx 0.2572\n$$\nThus, the expected proportion of affected offspring is approximately $0.2572$.",
            "answer": "$$\n\\boxed{0.2572}\n$$"
        },
        {
            "introduction": "The final piece of the puzzle is translating our molecular understanding into accurate clinical diagnosis. The unique genetic basis of Fragile X syndrome—a large, GC-rich repeat expansion—poses significant challenges for standard laboratory techniques like PCR. This case-based exercise will guide you through the interpretation of realistic molecular diagnostic results, forcing you to confront the phenomenon of 'allelic dropout' and appreciate why specific, multi-step testing algorithms involving Southern blotting are essential for a definitive diagnosis .",
            "id": "5145600",
            "problem": "A pediatric genetics clinic evaluates a child with suspected Fragile X syndrome. The laboratory follows a two-step algorithm for testing the Fragile X Messenger Ribonucleoprotein 1 (FMR1) gene: first, flanking-primer polymerase chain reaction (PCR) to size the Cytosine-Guanine-Guanine (CGG) repeat, and second, triplet-primed PCR (TP-PCR) to screen for expansions that are refractory to standard amplification. The child is a male aged $4$ years with global developmental delay and a maternal uncle with intellectual disability. The initial results are as follows:\n\n- Proband (male): Flanking PCR shows no amplicon under quality-controlled conditions where an internal control amplifies robustly; TP-PCR shows a characteristic ladder whose signal intensity progressively diminishes and plateaus around a repeat-equivalent of approximately $150$–$170$ CGG units.\n- Mother (female): Flanking PCR shows a single peak corresponding to approximately $30$ CGG repeats; TP-PCR shows a broad ladder with signal extending well beyond what is expected for $200$ CGG units.\n\nAssume high-quality genomic DNA, appropriate thermocycling, and optimized magnesium and dimethyl sulfoxide (DMSO) conditions. Consider the following fundamental bases:\n\n- PCR amplification requires strand denaturation, primer annealing, and polymerase extension; guanine-cytosine (GC)-rich sequences have higher melting temperature and can form stable secondary structures that impede polymerase progression.\n- In each cycle, the probability of fully traversing a difficult template segment of length $n$ can be idealized as $p(n)$ with $0<p(n)<1$, and if the segment length increases, $p(n)$ decreases. Across $k$ cycles, the expected yield scales approximately with the product of cycle-wise traversal probabilities, giving an exponential disadvantage to longer, structure-prone templates.\n- Methylation of cytosine within Cytosine-phosphate-Guanine (CpG) dinucleotides in the FMR1 promoter is commonly associated with full mutations (typically greater than $200$ CGG repeats) and transcriptional silencing. Southern blot using methylation-sensitive restriction enzymes can simultaneously assess repeat size and methylation, even for alleles that fail to amplify by PCR.\n\nWhich of the following statements best explain how PCR amplification bias for high CGG repeat sizes can lead to allelic dropout and specify the conditions under which Southern blot is required to detect full mutations and methylation status? Select all that apply.\n\nA. In a heterozygous female with one normal allele (approximately $30$ repeats) and one full mutation allele (greater than $200$ repeats), the per-cycle traversal probability $p(n)$ for the expanded allele is sufficiently low that, over $k$ cycles, the yield ratio of long to short alleles decays exponentially, making the expanded allele effectively invisible by flanking PCR (allelic dropout). Southern blot is indicated to detect the full mutation and determine methylation.\n\nB. In a male with a full mutation allele greater than $200$ repeats but an unmethylated promoter, flanking PCR reliably amplifies the expanded allele; therefore, Southern blot is unnecessary because methylation status can be inferred from PCR fragment size.\n\nC. In suspected size and methylation mosaicism in a male (mixture of premutation and full mutation cells, some methylated and some unmethylated), TP-PCR directly measures methylation status from peak intensity patterns across the ladder; therefore, Southern blot is generally unnecessary.\n\nD. When flanking PCR yields no product in a male despite internal control amplification, and TP-PCR produces a ladder that fades and plateaus around $150$–$170$ CGG units, the findings are consistent with amplification bias and allelic dropout of a very large expansion. Southern blot is indicated to size the expansion and assess methylation.\n\nE. In prenatal testing from chorionic villus sampling, PCR (flanking PCR plus TP-PCR) alone suffices to detect full mutations and methylation status if DNA quantity is high; Southern blot is not required because methylation patterns are uniform and independent of tissue context at this gestational stage.",
            "solution": "### Step 1: Extract Givens\n\n- **Proband:** Male, aged $4$ years, global developmental delay.\n- **Family History:** Maternal uncle with intellectual disability.\n- **Test 1:** Flanking-primer polymerase chain reaction (PCR) to size the Cytosine-Guanine-Guanine (CGG) repeat in the Fragile X Messenger Ribonucleoprotein 1 (FMR1) gene.\n- **Test 2:** Triplet-primed PCR (TP-PCR) to screen for expansions refractory to standard amplification.\n- **Proband Results:**\n    - Flanking PCR: No amplicon; internal control amplified.\n    - TP-PCR: Characteristic ladder; signal intensity progressively diminishes and plateaus around a repeat-equivalent of approximately $150$–$170$ CGG units.\n- **Mother Results:**\n    - Flanking PCR: Single peak corresponding to approximately $30$ CGG repeats.\n    - TP-PCR: Broad ladder with signal extending well beyond what is expected for $200$ CGG units.\n- **Technical Assumptions:** High-quality genomic DNA, appropriate thermocycling, and optimized magnesium and dimethyl sulfoxide (DMSO) conditions.\n- **Fundamental Principles:**\n    1.  PCR amplification difficulty increases with guanine-cytosine (GC)-rich sequences due to high melting temperature and stable secondary structures that impede polymerase.\n    2.  The probability of fully traversing a difficult template of length $n$, denoted $p(n)$, is between $0$ and $1$ ($0 < p(n) < 1$) and decreases as $n$ increases. Over $k$ cycles, this creates an exponential disadvantage for longer templates.\n    3.  Methylation of cytosine within Cytosine-phosphate-Guanine (CpG) dinucleotides in the FMR1 promoter is associated with full mutations (typically $> 200$ CGG repeats) and leads to transcriptional silencing.\n    4.  Southern blot analysis can simultaneously assess repeat size and methylation status, even for alleles that fail to amplify by PCR.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem statement is evaluated for validity.\n\n- **Scientifically Grounded:** The problem is firmly rooted in the established principles of molecular genetics, specifically the diagnosis of Fragile X syndrome. The descriptions of flanking PCR, TP-PCR, Southern blotting, allelic dropout, CGG repeat expansion, and FMR1 gene methylation are all factually and scientifically accurate. The probabilistic model of PCR efficiency ($p(n)$) is a valid and useful conceptual framework for understanding amplification bias.\n- **Well-Posed:** The problem provides a clear clinical scenario with specific lab results and asks for the correct interpretation based on a set of fundamental principles. The question is structured to have a discrete set of correct answers among the options.\n- **Objective:** The language is technical and free of subjective or opinion-based claims. The data and principles are presented objectively.\n- **Completeness and Consistency:** The information is self-contained and consistent. The mother's results (a normal allele and a large expansion) are consistent with her being a carrier, and the son's results (a very large, unamplifiable allele) are consistent with him having inherited that expansion. The data are not contradictory.\n- **Realism:** The scenario is highly realistic and represents a classic case encountered in pediatric genetics clinics for Fragile X syndrome testing.\n\n### Step 3: Verdict and Action\n\nThe problem statement is **valid**. It is scientifically sound, well-posed, and internally consistent. The solution process may proceed.\n\n### Derivation and Option Analysis\n\nThe central issue is the technical limitation of PCR in amplifying long, GC-rich tandem repeats, as found in the FMR1 gene. The probability of polymerase successfully traversing the repeat region, $p(n)$, is a function of the number of repeats, $n$. As $n$ increases, secondary structures (e.g., hairpins) become more stable, significantly reducing $p(n)$. In a standard PCR with $k$ cycles, the amount of product for an allele of length $n$ is a function of $(p(n))^k$. If a heterozygous individual has two alleles, one short ($n_S$) and one long ($n_L$), the ratio of the amplified products will be heavily skewed toward the shorter allele because $p(n_S) \\gg p(n_L)$, leading to $(p(n_S)/p(n_L))^k \\gg 1$. This preferential amplification of the shorter allele, to the point where the longer one is not detected, is known as \"allelic dropout.\"\n\nThe proband is male (hemizygous for the X-linked FMR1 gene). His flanking PCR failed (no amplicon), indicating his single allele is too large for this method. His TP-PCR shows a ladder that fades, which confirms an expansion but suggests its size is at or beyond the limits of even this specialized PCR technique, which is typical for large, methylated full mutations.\n\nThe mother is female. Her flanking PCR shows only a single allele at $30$ repeats. However, as she has an affected son, she must be a carrier of an expanded allele. Her TP-PCR confirms this, showing a ladder indicative of a large expansion. The flanking PCR result is a classic example of allelic dropout, where her normal allele (≈$30$ repeats) amplified efficiently but her expanded allele failed to amplify.\n\nSouthern blotting circumvents these PCR limitations. It does not rely on amplification but on restriction enzyme digestion and fragment size separation. It can therefore accurately size very large repeat expansions. Furthermore, by using a methylation-sensitive restriction enzyme alongside a control enzyme, it can definitively determine the methylation status of the FMR1 promoter.\n\nNow, we evaluate each option based on these principles.\n\n**A. In a heterozygous female with one normal allele (approximately $30$ repeats) and one full mutation allele (greater than $200$ repeats), the per-cycle traversal probability $p(n)$ for the expanded allele is sufficiently low that, over $k$ cycles, the yield ratio of long to short alleles decays exponentially, making the expanded allele effectively invisible by flanking PCR (allelic dropout). Southern blot is indicated to detect the full mutation and determine methylation.**\n\n- **Analysis:** This statement provides a precise and correct explanation of allelic dropout in a carrier female. It correctly invokes the probabilistic nature of PCR failure on long repeats ($p(n)$) over $k$ cycles to explain the phenomenon. The mother’s results perfectly illustrate this. It correctly identifies that Southern blot is the required confirmatory test to characterize the large, unamplified allele and assess methylation, which is crucial for her genetic counseling.\n- **Verdict:** **Correct**.\n\n**B. In a male with a full mutation allele greater than $200$ repeats but an unmethylated promoter, flanking PCR reliably amplifies the expanded allele; therefore, Southern blot is unnecessary because methylation status can be inferred from PCR fragment size.**\n\n- **Analysis:** This statement is fundamentally flawed. Flanking PCR does *not* reliably amplify full mutations ($> 200$ repeats). The amplification failure is primarily due to the repeat length and GC-content, not methylation status, although methylation can further inhibit polymerase activity. Therefore, the premise that PCR is reliable for full mutations is false. Consequently, the conclusion is also false; one cannot infer methylation status from a PCR fragment size, especially when the fragment cannot be reliably generated in the first place. Southern blot is the essential tool for both sizing large alleles and determining methylation.\n- **Verdict:** **Incorrect**.\n\n**C. In suspected size and methylation mosaicism in a male (mixture of premutation and full mutation cells, some methylated and some unmethylated), TP-PCR directly measures methylation status from peak intensity patterns across the ladder; therefore, Southern blot is generally unnecessary.**\n\n- **Analysis:** This statement incorrectly attributes a capability to TP-PCR. TP-PCR is a sizing assay, not a methylation assay. While methylation can influence PCR efficiency and thus alter peak patterns, this is an indirect, qualitative, and unreliable effect. It does not provide a direct or quantitative measure of methylation. To resolve size and methylation mosaicism, Southern blot is the gold standard and is absolutely necessary.\n- **Verdict:** **Incorrect**.\n\n**D. When flanking PCR yields no product in a male despite internal control amplification, and TP-PCR produces a ladder that fades and plateaus around $150$–$170$ CGG units, the findings are consistent with amplification bias and allelic dropout of a very large expansion. Southern blot is indicated to size the expansion and assess methylation.**\n\n- **Analysis:** This statement accurately interprets the proband's laboratory results. The failure of flanking PCR in a male indicates an allele that is too large to amplify (a form of \"allelic dropout\" on a single allele). The TP-PCR result confirms an expansion but shows the limits of the technique, which is a common finding for full mutations. The conclusion that these findings are consistent with a very large expansion and that Southern blot is the necessary next step for definitive sizing and methylation analysis is the correct diagnostic algorithm.\n- **Verdict:** **Correct**.\n\n**E. In prenatal testing from chorionic villus sampling, PCR (flanking PCR plus TP-PCR) alone suffices to detect full mutations and methylation status if DNA quantity is high; Southern blot is not required because methylation patterns are uniform and independent of tissue context at this gestational stage.**\n\n- **Analysis:** This statement contains multiple inaccuracies. First, as established, PCR-based methods like flanking PCR and TP-PCR do not determine methylation status. Special methylation-specific PCR (MSP) would be needed, but Southern blot remains the gold standard for simultaneous sizing and methylation. Second, the premise that FMR1 methylation patterns are \"uniform and independent of tissue context\" in early gestation is false. Methylation is a dynamic process during development, and tissue-specific patterns and mosaicism are known complexities in prenatal diagnosis of Fragile X, making Southern blot even more critical for an accurate diagnosis and prognosis.\n- **Verdict:** **Incorrect**.",
            "answer": "$$\\boxed{AD}$$"
        }
    ]
}